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CRISPR/Cas9 derived from the bacterial adaptive immunity pathway is a powerful tool for genome editing,
but the safety profiles of in vivo delivered Cas9 (including host immune responses to the bacterial Cas9
protein) have not been comprehensively investigated in model organisms. Nonalcoholic steatohepatitis
(NASH) is a prevalent human liver disease characterized by excessive fat accumulation in the liver. In this
study, we used adenovirus (Ad) vector to deliver a Streptococcus pyogenes–derived Cas9 system (SpCas9)
targeting Pten, a gene involved in NASH and a negative regulator of the PI3K-AKT pathway, in mouse liver.
We found that the Ad vector mediated efficient Pten gene editing even in the presence of typical Ad vector-
associated immunotoxicity in the liver. Four months after vector infusion, mice receiving the Pten gene-
editing Ad vector showed massive hepatomegaly and features of NASH, consistent with the phenotypes
following Cre-loxP-induced Pten deficiency in mouse liver. We also detected induction of humoral immunity
against SpCas9 and the potential presence of an SpCas9-specific cellular immune response. Our findings
provide a strategy to model human liver diseases in mice and highlight the importance considering Cas9-
specific immune responses in future translational studies involving in vivo delivery of CRISPR/Cas9.
INTRODUCTION
Rapidly advancing genome-editing technologies
hold great promise for realizing therapeutic gene
manipulation at the DNA level, and have triggered
much excitement in the gene therapy field.1,2 Parti-
cularly with the advent of the CRISPR/Cas9 plat-
form adopted from the bacterial adaptive immune
system, genome editing in mammalian cells and in a
range of model organisms has become increasingly
straightforward.3–5 One important application of
genome editing is to rapidly generate somatic mouse
models of certain human diseases,6–8 thus bypassing
the time- and resource-consuming genetic manipu-
lation from embryo transgenesis to breeding in
multiple rounds. For example, we have previously
showed that hydrodynamic injection of plasmidDNA
expressing an SpCas9 system to target cancer genes
in wild-type mice could yield cancer-related pheno-
types in liver.9–11 Despite being convenient, hydro-
dynamic injection can deliver plasmid DNA to only
about 20% of hepatocytes in mice,12 which limits
gene editing efficiency. To enhance delivery, several
groups have used viral vectors, especially the ade-
novirus (Ad) vector with large cargo capacity, to
systemically deliver SpCas9 into mouse liver for ei-
ther therapeutic purpose or disease modeling.13,14 In
these two studies, expected phenotypic outcomes
following targeted gene editing were described 3 and
14 days after Ad vector injection, respectively. How-
ever, it has been well documented that systemic Ad
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vector infection in immunocompetent mice triggers
strong immune responses to both viral gene and
transgene products in the liver that eventually clear
transduced hepatocytes.15 Therefore, information
about the sustainability of Ad vector-mediated gene
editing and the resulting phenotypic changes in the
liver remains elusive.
Another poorly characterized aspect of in vivo
CRISPR/Cas9 genome editing in mammals con-
cerns host immune responses mounted against the
bacteria-derived Cas9 protein. Theoretically, only
a single, transient delivery of CRISPR/Cas9 system
is required to make permanent genetic modifica-
tions, and such transient function may reduce off-
target effect.16,17 However, many of the Cas9 con-
structs used in vivo may express for a long time,
such as following recombinant adeno-associated
virus (rAAV)-mediated delivery.18 Under these
conditions, Cas9-specific immune responses, espe-
cially cytotoxic cellular responses, have the poten-
tial to destroy targeted cells and limit long-term
therapeutic efficacy.
Phosphatase and tensin homolog (PTEN) is fre-
quently mutated in many human sporadic cancers,
as well as in patients with cancer predisposition
syndromes such as Cowden disease.19 About half of
the patients with primary hepatoma show de-
creased or absent PTEN protein expression, al-
though PTEN does not mutate frequently in
hepatocytes. Moreover, reduced PTEN expression
is well correlated with increased tumor grade, ad-
vanced disease stage, and poor prognosis in pa-
tients with hepatocellular carcinoma (HCC). In a
mouse model generated by the Cre-loxP system,
hepatocyte-specific Pten deficiency led to massive
hepatomegaly (liver swelling) and steatohepatitis
(fatty liver disease), as well as adenomas or HCC at
older ages.20,21 In light of these health risk associ-
ations, it is clear that Pten plays an important role
in lipid metabolism, hepatocyte homeostasis, and
tumorigenesis in the liver.19
In this study, we used an Ad vector to deliver an
SpCas9 system targeting Pten in mouse liver, hy-
pothesizing that Ad vector-mediated somatic gene
editing can produce sustained liver phenotypes
despite potential confounding effects of Ad vector-
associated immune responses to transduced hepato-
cytes. We purposefully controlled the experimental
conditions closely to resemble those of the previously
published study of hydrodynamic injection of plasmid
DNA carrying the same sgRNA and SpCas9 expres-
sion cassettes,9 allowing us to compare gene editing
efficiency between these two methods. We found the
Ad vector-mediated delivery to be more efficient for
Pten gene editing than hydrodynamic injection two
weeks after treatment, although typical Ad vector-
associated immune responses and liver damage
were detected during this period of time. Four
months after infection, mice receiving the Pten
gene-editing Ad vector showed massive hepato-
megaly and steatohepatitis, consistent with the
phenotype following Cre-loxP-induced Pten defi-
ciency in mouse liver. In addition, evidence of both
humoral and cellular immunity against SpCas9
following systemic Ad vector-mediated CRISPR/
Cas9 delivery in mice was observed. To our knowl-
edge, this is the first study reporting SpCas9-
specific immune responses in mammals. These
findings indicate that delivery methodology can af-
fect Cas9-specific immune responses, and argue for
closemonitoring of Cas9-specific immune responses,
as well as engineering efforts to limit Cas9 immu-
nogenicity, in future translational studies involving
in vivo delivery of CRISPR/Cas9 system to model
organisms and human subjects.
MATERIALS AND METHODS
Recombinant Ad genome construction
and viral vector production
The SpCas9 cassette in Ad.sgPten was derived
from pX330,4 where a hybrid chicken beta-actin pro-
moter drives the expression of a codon-optimized
S. pyogenes Cas9 cDNA with 3· FLAG tag and
2· SV40 nuclear localization signal. U6 promoter-
driven sgRNA targetingPtenwas PCR-amplified and
cloned with the SpCas9 cassette into an Ad backbone
plasmid22 using the Gibson cloning method. The
guide RNA sequence is 5¢-gagaucguuagcagaaacaaa-
3¢. EGFP driven by the hybrid chicken beta-actin
promoter was cloned into a separate Ad backbone
plasmid. E1/E3-deleted Ad type 5 vectors were pro-
duced using standard methods by either ViraQuest,
Inc. (Ad.sgPten), or University of Massachusetts
Medical School Viral Vector Core (Ad.GFP).
Animal use
Eight-week-old FVB/NJ female mice were ini-
tially used to study Pten gene editing efficiency
and liver steatosis. In later studies characterizing
immune responses, 8–10-week-old FVB/NJ female
mice and 8-week-old C57BL/6 female mice were
used. All FVB/NJ mice were purchased from Jack-
son Laboratory, and all C57BL/6 mice were ob-
tained by in-house breeding. An amount of 2.5·
1010 viral particles (5 ·108 plaque-forming units,
PFU) diluted in 150ll of phosphate-buffered saline
(PBS) or equal volume of PBS without viral par-
ticles was delivered through tail vein injection.
All animal study protocols were approved by the
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University of Massachusetts Medical School In-
stitutional Animal Care and Use Committee.
Cell culture and infection with Ad vectors
Human embryonic kidney 293-T antigen trans-
formed (HEK293T) cells and a mouse cell line
carrying the oncogenic KrasG12D allele and in-
activated p53 (KP cells)23 were maintained under
standard cell culture conditions. Cells were seeded
in 24-well plates 1 day before infection, and in-
fected with Ad.GFP or Ad.sgPten. Seventy-two
hours later, cells were harvested and subjected to
the Surveyor nuclease assay as described below.
The gene-editing reporter cell line was created by
infecting HEK293 cells with lentiviral vectors to
induce stable gene integration. The GFP and
mCherry fluorescence was imaged 72 hr after
Ad.sgPten infection.
Surveyor nuclease assay
Genomic DNA was extracted from cell culture
using QE buffer (Epicentre) or from mouse liver
tissue using High Pure PCR Template Preparation
Kit (Roche). PCRwas performed usingHerculase II
High-Fidelity Polymerase (Agilent) to amplify the
DNA region of interest. PCR product was purified
with QIAquick Gel Extraction Kit (Qiagen), and
subjected to a Surveyor nuclease assay or to deep
sequencing (see description below). The Surveyor
nuclease assay was performed using the SUR-
VEYORMutation Detection Kit (Transgenomic) as
previously described,9 followed by electrophoresis
using a 4–20% Novex TBE Gel (Life Technologies)
with ethidium bromide staining.
Deep sequencing
Libraries were made from the purified PCR
products described in the Surveyor nuclease assay
according to the Nextera XT protocol, and se-
quenced on the Illumina Nextseq platform (75bp
paired-end). Standard Illumina sequencing analy-
sis procedures were adopted to process the data.9
Reads weremapped to thePten reference sequence,
and insertion/deletion mutations were determined
using VarScan2.
Histological analysis
Mice were humanely euthanized by CO2 as-
phyxiation followed by cervical dislocation. A por-
tion of liver was fixed in 10% formalin solution
overnight and embedded in paraffin, and 4-lm-
thick sections were stained with hematoxylin and
eosin. Three fields were imaged from each mouse
liver by an investigator blinded to the treatment
information.
Fluorescence microscopy of liver sections
Upon harvesting, a portion of liver tissue was
directly embedded in O.C.T. Compound (Tissue-
Tek) and stored under -80C until sectioning, and
8-lm-thick cryosections were collected and moun-
ted with VECTASHIELD Mounting Medium with
DAPI (Vector Laboratories). Native GFP signal and
DAPI nuclear staining were captured by a fluores-
cence microscope (Leica). Three fields were imaged
from each mouse liver by an investigator blinded to
the treatment information. GFP+ cells were coun-
ted using the Imaris 8.1.1 image processing pro-
gram (Bitplane). Briefly, using the 3D View option
in Imaris, total DAPI was counted based on
threshold intensity and cell diameter parameters.
Afterward, a GFP threshold was applied across all
images. DAPI and GFP signals above their respec-
tive thresholds that showed overlap were counted
as GFP+ cells. To calculate the percentage of GFP+
cells, the number of GFP+ cells was divided by total
DAPI. During automated analysis, cells on the edge
of each image were excluded.
Serum ALT and AST assays
Blood was collected by facial vein bleeding, and
serum was separated using a Microtainer tube
with serum separator (BD). ALT and AST levels
were assayed in duplicate using the ALT Color
Endpoint Reagent Kit and AST Color Endpoint
Reagent Kit (TECO Diagnostics), respectively, ac-
cording to the manufacturer’s instructions.
Reverse transcription-quantitative PCR
A portion of mouse liver was flash-frozen in liq-
uid nitrogen immediately following harvesting, and
stored under -80C until RNA extraction. Total
RNAwas extracted using Direct-zol RNAMiniPrep
Kit with DNase I treatment (ZYMO Research).
About 1.5lg of RNA was reverse transcribed using
theHigh-Capacity cDNAReverse TranscriptionKit
(Life Technologies). Multiplexed qPCR was per-
formed in triplicates using TaqMan reagents that
detect mouse Tnf-a (Life Technologies; Assay ID:
Mm00443258_m1) and Gapdh (Life Technologies;
cat # 4352339E), or mouse Ifn-c (Life Technologies;
Assay ID: Mm01168134_m1) and Gapdh. Tnf-a or
Ifn-c expression level was normalized to Gapdh.
Immunocytochemistry
Formalin-fixed paraffin-embedded liver sections
as described above (see Histological analysis sec-
tion) was immunostained using primary antibodies
against Pten (Cell Signaling; cat # 9559, 1:200),
CD4 (eBioscience; cat # 14-9766-82, 1:100), or
CD8a (eBioscience; cat # 14-0808-82, 1:100). Proper
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secondary antibodies were chosen according to the
host species of each primary antibody. Three fields
were imaged from each mouse liver by an investi-
gator blinded to the treatment information.
ELISA for SpCas9-specific antibody
Ninety-six-well Nunc MaxiSorp Plates (Thermo
Scientific) were coated with the SpCas9 protein
(0.5 lg/well, PNA Bio, cat # CP01) in 1 · coating
buffer diluted from Coating Solution Concentrate
Kit (KPL) overnight at 4C. The plates were wa-
shed with 1· wash buffer diluted from 20· Wash
Solution (KPL) and blocked with 1% BSA Blocking
Solution (KPL) for 1 hour at room temperature.
Mouse sera were diluted 1000-fold with 1% BSA
Diluent Solution (KPL), added to the wells, and
incubated for 1 hr at room temperature with
shaking (200 rpm). The mouse monoclonal anti-
body against SpCas9 (Epigentek; clone 7A9, cat #
A-9000-100) was serially diluted and used as a
standard to quantify IgG1. After washing, each
well was incubated with 100ll of HRP-labeled goat
anti-mouse IgG1, IgG2a, or IgG2b (Santa Cruz;
diluted 1:5000) for 1 hour at room temperature.
The wells were washed four times and incubated
with 100ll of ABTS ELISA HRP Substrate (KPL).
Optical density at 410nm was measured using a
Synergy HT microplate reader (BioTek). The IgG1
standard curve was generated using the four-
parameter logistic regression equation with the
Gen5 software (BioTek).
Cytokine release assay
Splenocytes were isolated from mice by mashing
freshly harvested spleen and passing through a
70lm cell strainer (BD). Red blood cells were lysed
using Red Blood Cell Lysis Buffer (Roche Diag-
nostics). Cell number and viability were determined
byGuavaViaCount assay (Guava Technologies). For
the cytokine release assay, 200,000 live cells per well
were seeded into a 96-well plate in 200ll complete
RPMI-1640 medium supplemented with 10% FBS
and 1% penicillin/streptomycin (Life Technologies).
Cells were incubated with or without the SpCas9
protein (5lg/ml, PNA Bio) at 37C/5% CO2. Three
days later, culture medium was collected after
Figure 1. Ad.sgPten functions in Pten gene editing in vitro. (A) Viral genome of Ad.sgPten. Also shown is the conserved target sequence of sgPten in mouse
and human genomes. The positions of start codon, sgPten binding site, and protospacer adjacent motif (PAM) are labeled. Predicted SpCas9 cleavage site is
indicated by red arrowhead. CBh, hybrid chicken beta-actin promoter; ITR, inverted terminal repeat. (B) Representative bright-field and fluorescence images of
cells harboring a gene-editing reporter system with or without Ad.sgPten infection. Integrated expression cassettes of GFP, sgGFP, and mCherry are depicted.
EF1a, elongation factor 1a promoter; PGK, phosphoglycerate kinase promoter. Circled areas indicate depletion of GFP in a subset of cells. (C) Surveyor assay to
detect mutations within targeted genomic region following Ad.sgPten infection of KP cell and HEK293T cells. Ad.GFP infection serves as control. Red arrows
indicate positive bands after mismatch-specific DNA nuclease digestion of PCR products.
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centrifugation, and the levels of IL-1b, IL-2, IL-6, IL-
10, IL-12 (p70), Ifn-c, and Tnf-a were measured by
the Bio-Plex Mouse Cytokine Assay (BioRad) ac-
cording to the manufacturer’s instructions, using a
Bio-Plex MAGPIX Multiplex Reader (Luminex).
Statistical analysis
Comparison between two groups was analyzed
by Student’s t-test. Comparison among three
groups was analyzed by one-way analysis of vari-
ance (ANOVA) followed by Tukey’s multiple com-
parison test to compare between two groups. All
analysis was performed using Prism 6 software
(GraphPad Software).
RESULTS
Ad-mediated Pten gene editing in vitro
We packaged an E1/E3-deleted Ad vector to co-
express SpCas9 and an sgRNA targeting the mouse
Pten gene (Ad.sgPtenhereafter) (Fig. 1A). To validate
SpCas9 expression and function from this Ad vector,
we used a gene-editing reporter cell line that stably
expresses GFP, mCherry, and an sgRNA targeting
the GFP gene (sgGFP). In the absence of Ad.sgPten
infection, almost all cells expressed both GFP and
mCherry (Fig. 1B). In contrast, Ad.sgPten infection
generated a cell population showing only mCherry
but not GFP, suggesting that SpCas9 expression
from Ad.sgPten together with sgGFP reconstituted a
functional CRISPR gene-editing system, and intro-
duced disruptive insertion/deletion (indel) mutations
in GFP as a result of error-prone nonhomologous
end-joining repair (Fig. 1B). The sgPten target se-
quence is conserved between the mouse Pten and
human PTEN genes (Fig. 1A), allowing us to test
Pten gene editing using Ad.sgPten in both mouse
(KP) and human (HEK293T) cell lines. In both cell
lines, Ad.sgPten infection resulted in indelmutations
in Pten as evidenced by Surveyor assay (Fig. 1C).
These results validated the Pten gene-editing func-
tion of Ad.sgPten.
In vivo Ad-mediated Pten gene editing models
steatosis in mouse liver
We then delivered Ad.sgPten into mouse liver to
examinePten gene editing efficiency and associated
phenotypic outcome in vivo. Eight-week-old female
FVB/NJ mice received 2.5·1010 particles/animal
through tail vein injection. We injected Ad.GFP
into another group of strain-, age-, and gender-
matched mice as a control (Fig. 2A). Mice were
sacrificed at different time points to examine gene
editing efficiency and phenotypic consequences
following Pten gene disruption in the liver. Two
Figure 2. In vivo adenovirus-mediated Pten gene editing models steatosis in mouse liver. (A) Cartoon showing tail vein injection of Ad vector to an adult
mouse. (B) Surveyor assay to detect Pten gene mutation in the liver two weeks after Ad vector infection. 1 and 2 indicate samples from two mice. Arrows
indicate positive bands. (C) Immunohistochemistry of liver sections showing loss of Pten staining in a subset of cells (arrows) one month after Ad vector
infection. The scale bars represent 100 lm, and 29 – 6% hepatocytes are Pten negative (n = 3). (D) Representative photographs of whole mouse liver harvested
four months after infection. A ruler with numbered unit in centimeter was included to gauge size. (E) Dot plot showing liver weight per body weight ratios of
five mice per treatment group four months after infection. Each dot represents one mouse. Mean values and standard deviations are plotted. ***p< 0.001 by t-
test. (F) Representative images of H&E staining of liver sections showing steatosis (lipid accumulation) in Ad.sgPten-infected mice (arrows) four months after
infection.
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weeks postinfection (p.i.), Surveyor assay using
liver genomic DNA revealed indel mutations (Fig.
2B). Deep sequencing confirmed the presence of
indels surrounding the predicted SpCas9 cleavage
site (Table 1). At one month after treatment, loss of
Pten immunostaining in liver sections was readily
observed (Fig. 2C), demonstrating successful Pten
gene disruption by error-prone indel mutations.
We have previously employed hydrodynamic in-
jection to deliver plasmid harboring the same
sgRNA and SpCas9 expression cassettes into
strain-, age-, and gender-matched mice, and indel
frequency in liver was estimated to be only about
3% two weeks postinjection.9 With Ad.sgPten, we
achieved total indel frequencies of 14.8% and 22.8%
in the two mice examined (Table 1 and Supple-
mentary Table S1; Supplementary Data are avail-
able online at www.liebertpub.com/hum), 5–8-fold
greater than that obtained with hydrodynamic in-
jection of plasmid.
Importantly, mice receiving Ad.sgPten showed
liver phenotypes recapitulating Pten genetic dele-
tion. Four months p.i., pale liver appearance and
dramatic hepatomegaly were observed in the mice
infected with Ad.sgPten (Fig. 2D). The ratio of liver
weight to bodyweightwas increased from about 5%
in Ad.GFP-infected mice to about 10% in Ad.sg
Pten-infected mice (Fig. 2E). H&E staining re-
vealed massive liver steatosis (accumulation of
lipid shown by arrows) in the mice infected by
Ad.sgPten, but not in themice infected by Ad.GFP
(Fig. 2F). These data demonstrated that Ad-
mediated Pten gene editing is a viable means
to rapidly generate somatic mouse model of liver
steatosis, and that Ad infection outperformed
plasmid hydrodynamic injection in inducing liver
Pten gene editing.
Ad.sgPten induced typical Ad vector-
associated immune responses
and liver damage
It is well known that immune responses associ-
ated with systemic delivery of Ad vectors can clear
infected hepatocytes and induce transaminitis that
indicates liver damage.15,24–26 Such a destructive
process might have eliminated some hepatocytes
that had undergone successful Pten gene editing,
and thus complicated our study. To estimate the
efficiency and kinetics of liver transduction over
time under our experimental setting (including our
specific mouse strain, gender, age, vector dose,
and route of administration [see Materials and
Methods for details]), we infected mice with an Ad
vector expressing GFP (Ad.GFP), and counted
GFP-positive cells in liver sections at 3, 7, and 14
days p.i. by fluorescence microscopy (Fig. 3A). This
time-course experiment revealed an expectedly
high but transient transduction rate of 80.8% of
liver cells 3 days p.i., which rapidly diminished to
45.3% seven days p.i. and to 1.4% fourteen days p.i.
(Fig. 3B). Correspondingly, serum liver transami-
nases ALT and AST were significantly elevated in
Ad.GFP- and Ad.sgPten-infected groups at 7 and
14 days p.i. (Fig. 3C), indicating substantial acute
liver damage.
We sacrificed a group of mice at 14 days to fur-
ther characterize the immunotoxicity in the liver.
Compared with PBS treatment, both Ad.GFP and
Ad.sgPten infections elicited similarly elevated ex-
pression of inflammatory cytokines including Tnf-a
and Ifn-c in the liver (Fig. 3D), indicative of innate
and/or T helper type 1 (Th1)-related immune re-
sponse. H&E staining of liver sections showed in-
flammatory cell infiltration following Ad.GFP and
Ad.sgPten infection (Fig. 3E). Immunocytochemistry
analysis identified CD4+ and CD8+ T-cells in the
liver sections of both Ad.GFP and Ad.sgPten groups
(Fig. 3F). Together, these data may represent well-
studied immune responses caused by Ad vector-
mediated gene transfer in the liver, which might
negatively affect the sustainability of Ad.sgPten-
mediated gene editing.However, it is possible that as
Pten-edited cells lost the inhibitory effect of Pten on
cell cycle and proliferation control, and rapidly pro-
liferated through clonal expansion during liver
damage and regeneration, the nonintegrating and
nonreplicating Ad vector genome was gradually di-
luted and eventually lost during hepatocyte division,
leaving the Pten-edited daughter cells spared from
immune attack. Studies are under the way to define
Table 1. Deep sequencing revealed insertion/deletion (indel)
mutations surrounding the predicted SpCas9 cleavage site
in mouse Pten gene
Mouse
Position in
reference
sequencea Reference Indelb
Reads
supporting
reference
Reads
supporting
indel
Indel
%
#1 124 A */ + C 5888 372 5.87
121 G */ -A 6925 193 2.65
Indels < 1% 6.28
Total 14.8
#2 124 A */ + C 5514 534 8.68
121 G */ -A 6670 206 2.91
124 A */ - C 5514 77 1.25
121 G */ -AA 6670 74 1.04
Indels < 1% 8.92
Total 22.8
aThe predicted SpCas9 cleavage site in reference is between positions
125 and 126, or three nucleotides upstream of the PAM sequence (Fig. 1A).
bOnly indels of a frequency > 1% are shown. See Supplementary Table
S1 for all indels. Indels are denoted as the changes downstream of the
reference nucleotide.
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the nature (i.e., viral- and/or transgene-directed) and
consequences (e.g., loss of transduced cells and vector
genomesand/or promoter shutdown) of such immune
responses.
Immune responses triggered by Ad vector in-
fection in the liver consist of two branches, namely,
the responses toward viral gene and transgene
products, respectively. These immune responses
can influence one another. Nonetheless, the robust
immunogenic setting following Ad.sgPten infection
provided us with a unique opportunity to study
SpCas9-specific immunity in vivo.
Detection of SpCas9-specific
immune responses
We further sought to examine the SpCas9-
specific immune responses, considering that they
may be relevant not only to disease modeling via
somatic mutagenesis but also to in vivo thera-
peutic applications. We developed an ELISA as-
say to quantify the antibody against SpCas9 in the
sera collected from Ad.GFP- and Ad.sgPten-in-
fected mice. Fourteen days p.i., robust IgG1 an-
tibody formation in all Ad.sgPten-infected mice
was detected, whereas the mice infected with
Ad.GFP showed nondetectable SpCas9-specific
IgG1 (Fig. 4A). To rule out a mouse strain-specific
effect, we infected age- and gender-matched
C57BL/6 mice with the same dose of either Ad.GFP
or Ad.sgPten, and detected SpCas9-specific IgG1 in
only the Ad.sgPten group (Fig. 4B). In addition, we
also detected SpCas9-specific IgG2a and IgG2b in
Ad.sgPten-infected mice (Fig. 4C, D).
To characterize the cellular response against
SpCas9, we isolated and cultured splenocytes from
PBS-, Ad.GFP-, and Ad.sgPten-treated mice, and
these splenocyteswere subjected to a cytokine release
assay with or without SpCas9 protein stimulation.
Figure 3. Ad vector-associated immune responses and liver damage. (A) Representative images of liver sections showing EGFP native fluorescence (green-
colored), nuclear staining by DAPI (red-colored), and merged signals at 3, 7, and 14 days postinfection (p.i.). The scale bar represents 100 lm. (B) Quantification
of percent of GFP-positive (GFP+ ) cells in liver at 3, 7, and 14 days postinfection. Three fields of each liver section from 4 to 5 mice per time point were
analyzed. Data are plotted as mean and standard deviation. ##p< 0.01 (among three time points) by one-way ANOVA. ***p< 0.001 (versus 3d p.i.) by Tukey’s
test. (C) Serum levels of alanine transaminase (ALT) and aspartate transaminase (AST) at pretreatment and 3, 7, and 14 days posttreatment. Data are plotted as
mean and standard deviation of 6–7 mice per treatment group in international unit per liter (IU/liter). ##p< 0.01 (among three treatment groups of the same time
point) by one-way ANOVA. ***p< 0.001 (versus Ad.GFP or Ad.sgPten) by Tukey’s test. (D) mRNA expression of Tnf-a (upper panel) and Ifn-c (lower panel)
normalized to Gapdh expression in mouse liver two weeks after treatment as determined by RT-qPCR. Each symbol represents one mouse. Mean values and
standard deviations are plotted. ##p< 0.01 (among three treatment groups) by one-way ANOVA. ***p < 0.001 (versus Ad.GFP or Ad.sgPten). nd, not detectable;
ns, not significant. (E) Representative H&E staining images of liver sections showing cell infiltration in Ad.GFP- and Ad.sgPten-infected mice 14 days p.i.
(arrows). The scale bars represent 50 lm. (F) Representative images by immunohistochemistry showing positive staining of CD4 (upper panels) and CD8 (lower
panels) in Ad.GFP- and Ad.sgPten-infected mice 14 days p.i. (arrows). Enlarged images of boxed areas are embedded. The scale bars represent 50lm.
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SpCas9 stimulation of splenocytes for three days
in vitro increased the levels of a range of cytokines
secreted in culturemedium, including IL-1b, IL-6, IL-
10, IL-12, Tnf-a, and Ifn-c. However, the increase in
these cytokines was not specific to splenocytes re-
covered from the Ad.sgPten-infected mice (Sup-
plementary Fig. S1). Interestingly, IL-2 secretion
from Ad.sgPten-primed splenocytes was signifi-
cantly increased from 50 to 175pg/ml upon SpCas9
stimulation, whereas the PBS and Ad.GFP-primed
control splenocytes showed decreased IL-2 (Fig.
4E). Increased IL-2 secretion from Th1 cells could
be associated with the development of CD4+ and/or
CD8+ T-cell responses. Here we did not intend to
define immune epitopes for B- and/or T-cell re-
sponses in SpCas9 and role of SpCas9-specific cy-
totoxic T lymphocyte (CTL) in the liver damage,
which will be addressed in our follow-up study.
Nonetheless, the data presented here indeed dem-
onstrated that SpCas9, as a foreign bacterial pro-
tein, could induce humoral immunity.
DISCUSSION
Ad vectors for human gene therapy have been
hampered by their destructive immunotoxicity.27
However, they may be well-suited to deliver the
CRISPR/Cas9 gene-editing system to model or-
ganisms such as mouse. First, the large cargo size
of Ad vector allows for packaging the entire
CRISPR/Cas9 system in one vector even with
multiplexed targeting capacity. Second, Ad vector
can transduce a broad range of cell types, including
dividing and quiescent cells, in vivo and with high
Figure 4. SpCas9-specific immune responses following Ad.sgPten infection in mice 14 days p.i. Detection of anti-SpCas9 IgG1 levels in FVB/NJ mouse sera
(A) and C57BL/6 mouse sera (B), anti-SpCas9 IgG2a (C), and IgG2b (D) levels in FVB/NJ mouse sera as determined by ELISA. Each symbol represents one
mouse. Mean values and standard deviations are also plotted. (E) IL-2 induction in cultured splenocytes isolated from PBS-, Ad.GFP-, or Ad.sgPten-infected
mice with (gray bars) or without (white bars) SpCas9 protein stimulation. Mean values from 6 to 7 mice per group are plotted with standard deviation. *p < 0.05;
**p< 0.01; ***p< 0.001.
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efficiency. Third, although Ad vector-mediated
gene expression is transient, it is believed that only
transient expression of CRISPR/Cas9 system is
required to induce permanent genome editing.
However, Ad vector-associated immune responses
are capable of clearing transduced hepatocytes
undermany experimental conditions. For example,
Cheng et al. delivered a CRISPR/Cas9-nickase Ad
vector targeting Cebpa to mouse liver through tail
vein injection, and they observed about 50% loss of
both Ad vector genome andCas9 expression in liver
7 days p.i., and nearly complete loss 3 months
p.i., suggesting efficient clearance of Ad vector-
transduced liver cells.14 This and another proof-
of-concept study13 employing an Ad vector for
CRISPR/Cas9 genome editing inmouse liver showed
short-term phenotypic outcome up to 7 days p.i.,
meanwhile raising the question of whether the gene-
editing effects would be preserved over a longer pe-
riod of time after clearance of initially transduced
liver cells. This is important for disease model-
ing since a stable phenotype may be required to
study disease mechanism or to evaluate therapeutic
intervention.
Here, we demonstrated that Pten gene editing in
mouse liver by Ad vector-mediated CRISPR/Cas9
somatic gene editing could induce steatosis at 4
months p.i., although typical Ad vector-associated
immune responses and liver damage were readily
detected at 14 days p.i. and earlier. Our results sup-
port using Ad vectors to deliver a genome-editing
system inmouse liver for long-term human disease
modeling, turning the shortcoming of transient
in vivo transduction by Ad vector into an advantage.
However, we cannot rule out the possibility that si-
lencingPten, a known tumor suppressor gene,might
provide edited liver cells with a growth advantage
during liver damage and regeneration, which might
contribute to shaping the liver phenotype at 4
months p.i. In addition, using the same experi-
mental setting as the previous report utilizing
hydrodynamic injection to deliver Cas9 and sgPten,
we achieved up to 22.8% Pten gene editing efficiency
with Ad.sgPten compared with only 3% with hy-
drodynamic injection 14 days posttreatment,9 fur-
ther supporting the advantage of Ad vectors in
inducing gene editing in mouse liver.
In recent nonhuman primate studies and gene
therapy clinical trials using rAAV vector as a gene
delivery platform, investigators found that vari-
ous host immune responses directed against the
transgene product or rAAV capsid can compromise
therapeutic efficacy.28–30 As CRISPR/Cas9 genome
editing is an appealing approach to directly re-
pairing disease-related gene mutations in situ,10,31
characterizing Cas9-specific host immune re-
sponses following gene delivery, and the develop-
ment of needed precautions or workarounds will be
necessary features in future translational studies.
We demonstrated that systemic Ad.sgPten delivery
inmice elicited SpCas9-specific immune responses,
including the generation of antibodies against
SpCas9 as well as increased IL-2 secretion from
Ad-sgPten-primed splenocytes upon SpCas9 pro-
tein stimulation. Notably, although our current
study provided no direct evidence of a SpCas9-
specific CTL response, we are in the process of
constructing an SpCas9 short peptide library and
defining immune epitopes for further study of
SpCas9-specific immunity. It should be noted that
the SpCas9-specific immune responses character-
ized in this studywere generated following systemic
Ad vector delivery. The strong immune adjuvant
effect of Ad vector infection32 and the steatohepati-
tis induced by Pten genome editing may contribute
to or escalate the formation of adaptive immune
responses against SpCas9. Therefore, SpCas9-
specfic immune responses should be further studied
during the use of other in vivo gene delivery plat-
forms and in other species. Furthermore, a proper
delivery method should be carefully chosen and
optimized to avoid any negative impact of such im-
mune responses.
To minimize off-target effect, transient in vivo
delivery of Cas9 (e.g., by direct delivery of protein)
was attempted.16 Provided that Cas9-specific im-
munotoxicity could negatively affect therapeutic
efficacy, a short-term immune suppression may be
sufficient to ensure gene editing during the tran-
sient presence of Cas9. However, we envision sev-
eral cases where Cas9 expression is sustained. For
example, rAAV-delivered Cas9 expression in vivo
has the potential to last for years and even an en-
tire lifetime in recipients. In addition, the catalyt-
ically deadCas9 (dCas9) fusedwith effector protein
domains has been shown to either activate or si-
lence specific gene expression at the transcrip-
tional level, representing a versatile approach to
regulating gene expression.33–35 This usually re-
quires the continuing presence of dCas9 effector to
exert a stable gene regulatory effect. Potential
immune responses against Cas9, such as a cyto-
toxic T-cell response attacking transduced and
edited cells marked by anMHC I-Cas9 epitope, can
limit therapeutic efficacy. Under these circum-
stances, developing novel methods of controlling
Cas9 expression in vivo will be valuable.16,36–38 In
addition, by using proper effector domains to fuse
with dCas9, permanent transcriptional regulation
through epigenetic modulation may be possible.
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In summary, we successfully employed an Ad
vector to deliver aCRISPR/Cas9-mediatedPtengene-
editing system to mouse liver, and achieved a liver
phenotype consistent with genetic Pten deficiency at
4 months p.i., thus supporting the use of Ad vector-
mediated genome editing for somatic disease model-
ing in mice. The SpCas9-specific immune responses
detected following Ad.sgPten infection in mice war-
rant further investigation into the nature of the im-
munogenicity, the optimal method of Cas9 delivery
and expression, and its potential impact on gene
editing efficiency in future translational studies.
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